Scarica l'app Stockscreener
10.52
2.63%
0.27
Adma Biologics Inc Borsa (ADMA) Ultime notizie
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - Barchart.com
Earnings Preview: ADMA to Report Financial Results Post-market on May 06 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ... - Caledonian Record
ADMA stock downgraded by Cantor as ‘channel stuffing’ claims shake investor confidence - MSN
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vanguard (NASDAQ: ADMA) reports 12.11M shares, 5.08% stake - Stock Titan
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
Immunoglobulin Market Leading Players AnalysisADMA - openPR.com
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
Investigation into ADMA Biologics for Potential Securities Fraud - Intellectia AI
ADMA Biologics (NASDAQ:ADMA) Stock Rating Lowered by Zacks Research - MarketBeat
ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA ... - Caledonian Record
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Yahoo Finance
ADMA Biologics Investor News: If You Have Suffered Losses - GlobeNewswire
ADMA Biologics rejects claims made in short-seller report - MSN
ADMA Biologics drops amid short report from Culper Research - MSN
ADMA Biologics extends selloff as Cantor downgrades after short report - MSN
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
Q2 2025 ADMA Biologics Inc Earnings Call Transcript - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: Could an 83% Potential Upside Be Within Reach? - DirectorsTalk Interviews
ADMA Biologics gains after refuting short seller claims - MSN
Canaccord’s Support and Short-Seller Rebuttal Could Be A Game Changer For ADMA Biologics (ADMA) - Yahoo Finance
Does ADMA Biologics' growth story outweigh short-seller concerns? - MSN
ADMA stock drops 6% after Culper Research alleges channel stuffing - MSN
Down 27% in 4 weeks, here's why Adma Biologics (ADMA) looks ripe for a turnaround - MSN
MSN Money - MSN
Wall Street Zen Upgrades ADMA Biologics (NASDAQ:ADMA) to Buy - MarketBeat
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqu - GuruFocus
Precision Trading with Adma Biologics Inc (ADMA) Risk Zones - Stock Traders Daily
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends - Insider Monkey
ADMA Legal Notification: ADMA Biologics Securities Class - GlobeNewswire
Is ADMA Biologics (ADMA) Falling Share Price Creating A Potential Opportunity For Investors - simplywall.st
ROSEN, LEADING INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - TMX Newsfile
Top 10 AI-Powered Biotech Stocks to Buy Right Now - Insider Monkey
ADMA Biologics Inc (ADMA) posts six percent Q4 2025 EPS beat, shares climb 0.85 percent in today’s session. - Xã Thanh Hà
ADMA Biologics Inc (ADMA) delivers Q4 2025 EPS beat, shares rise 2.51 percent on positive investor sentiment.Meme Stock - Cổng thông tin điện tử tỉnh Lào Cai
ADMA Biologics Inc (ADMA) posts Q4 2025 EPS above analyst forecasts, shares rise modestly on positive investor sentiment.Most Watched Stocks - UBND thành phố Hải Phòng
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):